Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04146337
Other study ID # 0338-19
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date October 12, 2020
Est. completion date June 30, 2022

Study information

Verified date November 2022
Source Rambam Health Care Campus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

2:1, open-label, single center, randomized controlled trial comparing FMT vs. no intervention for CRE carriers,


Description:

Antibiotic resistance has emerged worldwide and is of major concern leading to multidrug resistant (MDR) bacteria that are widely spread and are a major factor in morbidity and mortality in health-care settings. Among MDRs, carbapenem resistant Enterobacteriaceae (CRE) are of special concern, receiving the highest classification of "urgent threat level" in the US President Report. Consistent mortality rates of 40-50% are observed among inpatients with infections caused by CRE in hospitals worldwide, related mainly to unavailable, delayed or ineffective antibiotic treatment options. The extremely high mortality rates of patients with CRE infections have driven efforts to prevent the acquisition and spread of these bacteria in hospitals. These include screening for carriage, contact isolation of carriers, cohorting, dedicated healthcare staff and other infection control measures. These strategies have been proven as effective but are cumbersome and expensive. In most locations these strategies failed to completely eradicate CRE endemicity. CRE decolonization (eradication of colonization) might offer a double benefit: reducing the risk for the individual carrier to develop an infection due to the resistant strain (by that, potentially lowering the mortality risk) and preventing the bacteria from spreading to other patients, exposing them to the same hazard. Fecal microbiota transplantation (FMT), in which fecal material enriched with commensal microorganisms is transferred from a healthy donor, have proven efficacy in the treatment of recurrent Clostridium difficile infection (CDI) in multiple trails. Major adverse events that has been reported so far are mostly related to the route of administration (aspiration during nasogastric tube administration/colonoscopy). Other adverse events include mostly GI related symptoms (diarrhea, nausea, belching) and are self limited and resolve in few hours. FMT seems to be safe and effective both in immunocompetent and immunocompromised patients. The high efficacy of FMT in the treatment of a multi-drug resistant pathogen such as Clostridium difficile, suggest that it might be an efficient tool for other MDR pathogens (e.g. CRE). The potential of FMT to restore the gut microbiome and compete with residual resistant strains offer a novel way to fight the current MDR epidemic. The investigators aim to assess the effects of FMT on colonization and clinical infections with CRE. The investigators will apply FMT on a cohort of CRE carriers in a single center in Israel. FMT will be given by capsules for 2 consecutive days followed by rectal sampling at predefined time-point in the following 6 months.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date June 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility We will include adult inpatients =18 years positive for CRE of any strain and resistance mechanism in rectal surveillance stool samples, with or without CRE clinical samples. We will mandate a positive rectal swab within one week before randomization. Several exclusion criteria may change throughout the patients' hospitalization and we will follow-up patients for these criteria until reaching eligibility or not (designed as (for follow-up)). Non-eligible patients discharged will be re-evaluated for inclusion when re-admitted. We will exclude: - Pregnant women - Patients with severe neutropenia (<100/µl) (for follow-up) - Severe GVHD involving the gastrointestinal involvment (for follow-up) - Patients with inflammatory bowel disease (Crohn's or ulcerative colitis) - Patients with intestinal perforation or severe abdominal infection (for follow-up) - Patients carrying a colostomy, ileostomy or similar - Inability or contra-indication to take oral medications (intestinal obstruction, suspected perforation, peritonitis) (for follow-up) - Severe food allergies - Severe diarrhea (for follow-up) - Inability to provide informed consent (for follow-up) - Refusal of primary care physician - Patients treated with antibiotics within the 2 days before fulfilling all other eligibility criteria (for follow-up)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
FMT
Fecal microbiota in frozen capsules

Locations

Country Name City State
Israel Rambam Health Care Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary CRE eradication Number of participants achieving CRE eradication at 28 days, defined as 3 consecutive negative rectal cultures, with polymerase chain reaction preformed in the last sample. For patients with clinical infections, eradication definition will include a negative culture from the site of infection, if relevant at the time of eradication. 28 days
Secondary CRE eradication rates at day 7, day 14, and 3 & 6 months Number of participants achieving CRE eradication rates at day 7, day 14, and 3 & 6 months days 7, 14, months 3, 6
Secondary Mortality Number of participants who died by 28-day and 6 month 28-day and 6 months
Secondary Bacteremia Number of participants with CRE bacteremia and any bacteremia 6 months
Secondary CRE infection Number of participants with non-bacteremic new clinically-significant CRE infections 6 months
Secondary Hospitalization days Totals days in-hospital 6 months
Secondary Adverse events Number of participants with: pneumonia within a week after the intervention; dyspeptic complaints collected at the time of rectal sampling; changes in bowel habit including diarrhea and constipation; discontinuation of FMT before completing the study protocol 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06051513 - Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection N/A
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Completed NCT04167228 - Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Enrolling by invitation NCT03924934 - Community-associated Highly-Resistant Enterobacterales
Recruiting NCT04583098 - The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
Recruiting NCT04535661 - Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Terminated NCT05258851 - Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Phase 3
Not yet recruiting NCT04746222 - Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization Phase 2/Phase 3
Recruiting NCT04014413 - Safety and Efficacy of Fecal Microbiota Transplantation N/A
Recruiting NCT05871476 - Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals N/A
Recruiting NCT05850871 - Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies N/A
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Not yet recruiting NCT06210542 - Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Not yet recruiting NCT05981430 - Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae N/A
Recruiting NCT06258551 - Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Recruiting NCT05979545 - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Phase 4
Completed NCT04790565 - Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae Phase 2/Phase 3